Best OG - Search Results

1

Lipid uptake in chronic lymphocytic leukemia.

Thurgood LA, Best OG, Rowland A, Lower KM, Brooks DA, Kuss BJ. Thurgood LA, et al. Among authors: best og. Exp Hematol. 2022 Feb;106:58-67. doi: 10.1016/j.exphem.2021.12.193. Epub 2021 Dec 8. Exp Hematol. 2022. PMID: 34896245 Free article.

2

Surface profiles for subclassification of chronic lymphocytic leukemia.

Huang PY, Best OG, Belov L, Mulligan SP, Christopherson RI. Huang PY, et al. Among authors: best og. Leuk Lymphoma. 2012 Jun;53(6):1046-56. doi: 10.3109/10428194.2011.631370. Epub 2012 Apr 3. Leuk Lymphoma. 2012. PMID: 22023531 Review.

3

Hsp90 Inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells.

Che Y, Best OG, Zhong L, Kaufman KL, Mactier S, Raftery M, Graves LM, Mulligan SP, Christopherson RI. Che Y, et al. Among authors: best og. J Proteome Res. 2013 Apr 5;12(4):1710-22. doi: 10.1021/pr301055y. Epub 2013 Mar 22. J Proteome Res. 2013. PMID: 23458665

4

Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.

Huang PY, Best OG, Almazi JG, Belov L, Davis ZA, Majid A, Dyer MJ, Pascovici D, Mulligan SP, Christopherson RI. Huang PY, et al. Among authors: best og. Leuk Lymphoma. 2014 Sep;55(9):2085-92. doi: 10.3109/10428194.2013.867486. Epub 2014 Jan 24. Leuk Lymphoma. 2014. PMID: 24289109

5

A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.

Hotinski AK, Best OG, Thurgood LA, Lower KM, Kuss BJ. Hotinski AK, et al. Among authors: best og. Br J Haematol. 2021 Feb;192(3):e77-e81. doi: 10.1111/bjh.17257. Epub 2020 Dec 5. Br J Haematol. 2021. PMID: 33278845 Free article. No abstract available.

6

The future of laboratory testing in chronic lymphocytic leukaemia.

Hotinski AK, Best OG, Kuss BJ. Hotinski AK, et al. Among authors: best og. Pathology. 2021 Apr;53(3):377-384. doi: 10.1016/j.pathol.2021.01.006. Epub 2021 Mar 5. Pathology. 2021. PMID: 33678426 Review.

7

Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.

Do C, Best OG, Thurgood L, Hotinski A, Apostolou S, Mulligan SP, Lower K, Kuss B. Do C, et al. Among authors: best og. Br J Haematol. 2021 May;193(3):556-560. doi: 10.1111/bjh.17394. Epub 2021 Apr 13. Br J Haematol. 2021. PMID: 33851417 Clinical Trial.

8

Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.

Fatima N, Crassini KR, Thurgood L, Shen Y, Christopherson RI, Kuss B, Mulligan SP, Best OG. Fatima N, et al. Among authors: best og. Cancer Drug Resist. 2020 May 11;3(3):532-549. doi: 10.20517/cdr.2019.111. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582439 Free PMC article. Review.

9

The Role of Cholesterol in Chronic Lymphocytic Leukemia Development and Pathogenesis.

White AM, Best OG, Hotinski AK, Kuss BJ, Thurgood LA. White AM, et al. Among authors: best og. Metabolites. 2023 Jun 27;13(7):799. doi: 10.3390/metabo13070799. Metabolites. 2023. PMID: 37512506 Free PMC article. Review.

10

The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.

Fatima N, Shen Y, Crassini K, Burling O, Thurgood L, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. Fatima N, et al. Among authors: best og. Leuk Lymphoma. 2024 May;65(5):585-597. doi: 10.1080/10428194.2023.2300055. Epub 2024 Jan 16. Leuk Lymphoma. 2024. PMID: 38227293

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page